Clinical Trial

Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to patients with multiple myeloma prior to and following high-dose melphalan and autologous stem cell transplantation (ASCT), in conjunction with standard lenalidomide maintenance. We hypothesize that administration of belantamab mafodotin as part of autologous stem cell transplant consolidation and maintenance will be safe, well tolerated, and efficacious in comparison to historical data.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07-11 -> 2026-11-01 2026-08-11
minor Completion pushed: 2026-07-11 -> 2028-11-01 2026-08-11
Trial Details
NCT Number NCT04680468
Lead Sponsor University of Pennsylvania
Collaborators: GlaxoSmithKline
Conditions Myeloma
Enrollment 41 participants
Start Date 2021-06-02
Primary Completion 2026-11-01 (estimated)
Study Completion 2028-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-10